Fanapt

Vanda Pharmaceuticals has paused development of VQW-765 after a 546-patient Phase 3 study failed to demonstrate a significant reduction in social anxiety symptoms. The setback removes a near-term clinical catalyst, placing greater importance on its commercial product launches, cash position and remaining regulatory milestones.